Methods of treating heart failure with cardiac sarcomere activators
View Patent ↗Provided herein are methods of treating a subject with heart failure, comprising administering to the subject an initial dose of a cardiac sarcomere activator (CSA) for an initial time period, and subsequently administering to the subject a dose of the CSA based on the subject's plasma concentration of the CSA at the end of the initial time period.
1. A method of treating a subject with heart failure (HF), comprising:
a. administering to the subject an initial dose of a cardiac sarcomere activator (CSA) for an initial time period of at least about 2 weeks,
b. subsequently administering to the subject a dose of the CSA for a second time period based on the subject's plasma concentration of the CSA,
wherein when the subject's plasma concentration of the CSA is less than a threshold concentration of 300 ng/mL, the dose that is subsequently administered to the subject is greater than the initial dose;
wherein the CSA is omecamtiv mecarbil, or a pharmaceutically acceptable salt thereof; and wherein the dose that is subsequently administered to the subject is about 50 mg twice daily, about 37.5 mg twice daily, or about 25 mg twice daily.
2. The method of claim 1 , wherein the treatment is effective to achieve a target plasma concentration of about 300 ng/mL to about 750 ng/mL in the subject.
3. The method of claim 1 , wherein the subject has chronic heart failure, or a New York Heart Association Class II or III heart failure.
4. The method of claim 1 , wherein the subject has a left ventricular ejection fraction of about 40% or lower.
5. The method of claim 1 , wherein the CSA is administered orally to the subject.
6. The method of claim 1 , wherein the initial time period is about 4 weeks.
7. The method of claim 1 , wherein the subject's plasma concentration of the CSA is measured at about 2 weeks after the first administration of the initial dose.
8. The method of claim 6 , wherein the subject's plasma concentration of the CSA is measured at about 2 weeks after the first administration of the initial dose.
9. A method of treating heart failure (HF) in a subject in need thereof, comprising:
a. administering to the subject an initial dose of a cardiac sarcomere activator (CSA) for an initial time period,
b. subsequently administering to the subject a dose of the CSA for a second time period based on the subject's plasma concentration of the CSA,
wherein when the subject's plasma concentration of the CSA is less than a threshold concentration of 300 ng/mL, the dose that is subsequently administered to the subject is greater than the initial dose; and wherein the CSA is omecamtiv mecarbil, or a pharmaceutically acceptable salt thereof.
10. The method of claim 9 , wherein the dose that is subsequently administered to the subject is about 50 mg twice daily.
11. The method of claim 9 , wherein the dose that is subsequently administered to the subject is about 37.5 mg twice daily.
12. The method of claim 9 , wherein the dose that is subsequently administered to the subject is about 25 mg twice daily.
13. The method of claim 9 , wherein the CSA is omecamtiv mecarbil dihydrochloride hydrate.
14. The method of claim 9 , wherein the treatment is effective to achieve a target plasma concentration of about 300 ng/mL to about 750 ng/mL in the subject.
15. The method of claim 9 , wherein the initial time period is at least about 2 weeks.
16. The method of claim 9 , wherein the initial time period is about 4 weeks.
17. The method of claim 9 , wherein the subject's plasma concentration of the CSA is measured at about 2 weeks after the first administration of the initial dose.
18. The method of claim 9 , wherein when the subject's plasma concentration of the CSA is greater than or equal to 300 ng/mL, the dose that is subsequently administered is the same as the initial dose.
19. The method of claim 9 , wherein the subject has chronic heart failure, or a New York Heart Association Class II or III heart failure.
20. The method of claim 9 , wherein the subject has a left ventricular ejection fraction of about 40% or lower.
21. The method of claim 9 , wherein the subject has a plasma concentration of NT-proBNP of at least about 200 pg/mL.
22. The method of claim 9 , wherein the CSA is administered orally to the subject.
23. The method of claim 9 , wherein the method further comprises administering to the subject a third dose of the CSA for a third time period that follows the second time period based on the subject's second plasma concentration of the CSA.
24. The method of claim 23 , wherein the subject's second plasma concentration of the CSA is measured at about 6 weeks after the first administration of the initial dose.
25. The method of claim 23 , wherein the second time period is at least about 2 weeks.
26. The method of claim 23 , wherein the third dose of the CSA is the same as the second dose when the subject's second plasma concentration of the CSA is less than about 750 ng/ml.
27. The method of claim 23 , wherein the third dose of the CSA is less than the second dose when the subject's second plasma concentration of the CSA is greater than or about 1000 ng/ml.
28. The method of claim 23 , wherein the third dose is about 25 mg twice daily.
29. The method of claim 23 , wherein the third dose is about 37.5 mg twice daily.
30. The method of claim 23 , wherein the third dose is about 50 mg twice daily.